Glukagonlignende peptid 1-receptoragonisten semaglutid
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Semaglutide is a glucagon-like peptide-1 receptor-agonist (GLP-1 RA), which is injected subcutaneously once a week for treatment of Type 2 diabetes. In this review, the present results of semaglutide treatment are presented. Semaglutide has been evaluated in more than 8,000 patients across the spectrum of Type 2 diabetes. Trials with semaglutide have demonstrated superiority with sustained improved glycaemic control and weight loss compared to oral antidiabetic agents, other GLP-1 RAs and basalinsulin. In addition, semaglutide significantly decreased the occurrence of cardiovascular events compared with standard pharmacological diabetic treatment combined with placebo.
Bidragets oversatte titel | The glucagon-like peptide-1 receptor-agonist semaglutide |
---|---|
Originalsprog | Dansk |
Artikelnummer | V03190155 |
Tidsskrift | Ugeskrift for Laeger |
Vol/bind | 181 |
Antal sider | 5 |
ISSN | 0041-5782 |
Status | Udgivet - 2019 |
- Blood Glucose, Diabetes Mellitus, Type 2/drug therapy, Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptides/therapeutic use, Humans, Hypoglycemic Agents/therapeutic use
Forskningsområder
Links
- https://ugeskriftet.dk/videnskab/glukagonlignende-peptid-1-receptoragonisten-semaglutid
Forlagets udgivne version
ID: 241276061